|
Post by mnkdfann on Jan 28, 2020 20:54:27 GMT -5
40m shares would only cost $70m to buy. If the company can show the world that it can grow Afrezza scripts, we don't need shorts to buy back those shares. There are plenty of money out there looking for good deals. Just check out the recent move of my few other holdings: $NK, $NH, $TRIL. In all seriousness, I’m not trying to disrespect you, but if you think you can buy 40mm shares at the current price you should not be invested in this stock and should instead have your money in index ETF’s. Well, this may not be the case for a private individual, but were a hedge fund to approach Mannkind and offer to buy 40m shares via a financing, Mannkind would probably sell the shares at a discount to the current price. (Of course, Mannkind would have to have the shares to sell. Otherwise the deal would have to wait until they did.) Something like the above is alleged to have happened with Aphria last week ($100-million in shares from an unnamed institutional investor, purchased at better than a 10% discount).
|
|
|
Post by mnkdfann on Jan 28, 2020 20:02:20 GMT -5
|
|
|
Post by mnkdfann on Jan 28, 2020 13:17:50 GMT -5
Don't understand why people speculate that. Does Amgen have any diabetes related business? Because the management team and board are infested by ex-Amgen people. And it's mostly just one guy pushing this, mostly on StockTwits. Somehow claims the buyout is going to be at $50+ PPS. So, Mannkind is like Amgen's Minor League (AAA? AA?) team?
|
|
|
Post by mnkdfann on Jan 27, 2020 15:09:21 GMT -5
MNKD doesn’t really track the broad markets. Generally speaking I agree, but IMO it most certainly has tracked the markets over the past month's overall market melt-up. I'm very suspicious of the move, and that is part of why I sold a little while back once I was in the green.
|
|
|
Post by mnkdfann on Jan 26, 2020 11:55:50 GMT -5
Just some very random thoughts of mine here in Japan on a Sunday night. Curious to know others opinion on the idea of Afrezza coming off patient. I know we still have more than a decade of protections remaining, but the idea that Afrezza is not possible with out the the inhaler. Not sure what you were trying to say there, but some Afrezza users on the facebook page recently wrote about how they often breathed from a slightly opened cartridge directly, without using the inhaler. No idea if that is a good idea, but their claim was that it still worked.
|
|
|
Post by mnkdfann on Jan 26, 2020 2:42:07 GMT -5
The last few weeks were crazy in the markets. All sorts of stocks were up huge. Was MNKD's rise specific to the company or just a part of the overall melt-up? Time will tell. I sold all my MNKD shares a few weeks ago, so I am just watching at this point.
|
|
|
Post by mnkdfann on Jan 23, 2020 15:24:50 GMT -5
Something like or very close to of “up to $102M or $104M plus low double digit royalties on sales”. I think we received $1M a few Decembers ago when the stock needing some pumping and that was it. boca1girl wrote this a while back: mnkd.proboards.com/post/145123/threadMNKD received $1M. There were no details provided regarding any future “potential” milestone payments that I recall. Nothing on timing or achievements required to earn the milestone payments. “Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.”
|
|
|
Post by mnkdfann on Jan 23, 2020 13:23:59 GMT -5
|
|
|
Post by mnkdfann on Jan 23, 2020 11:33:28 GMT -5
|
|
|
Post by mnkdfann on Jan 23, 2020 11:29:06 GMT -5
It took them until 1/9/2020 to get around to filing an application to trademark 'Mannkind'?
|
|
|
Post by mnkdfann on Jan 21, 2020 22:20:50 GMT -5
|
|
|
Post by mnkdfann on Jan 21, 2020 13:12:56 GMT -5
(let's stay on topic this time) Is this the effects of the expiration on Friday and pent up demand caused by MLK Day? It may be that fantastic news is coming out tonight. Or it may be MNKD is caught in the market melt-up. Even though most of the indices are down today, a lot of stocks are (somewhat inexplicably, IMO) still hitting 52 week highs. Crazy. I sold my MNKD shares some weeks ago, but this is still fun to watch. FWIW, I sold a bunch of my other stocks today. I'm getting nervous. Overall, I'm still pretty long in the market, though.
|
|
|
Post by mnkdfann on Jan 20, 2020 16:45:56 GMT -5
Offhand, I'm not sure where MNKD LEAPS trade. CBOE? Or NYSE American options exchange? What I posted below (or something like it) may be relevant (specifically the bit I emboldened), and explain why 2022 LEAPS did not show up for MNKD and the other companies I listed earlier: www.elitetrader.com/et/threads/new-leap-rollout-process.334317/07/19/2019, 14:46 NYSE OPTIONS: 2022 LEAP INTRODUCTION New LEAP series expiring in January 2022, will be added for all qualifying issues for trading on Monday, September 16, 2019, regardless of the underlying’s expiration cycle. Previously, new LEAP series were added over a three month period (September, October, November), depending on the expiration cycle assigned to the class. A recent amendment to the Options Listing Procedure Plan approved adding all new LEAPs in September in an effort to reduce investor confusion. Participants are reminded that new LEAP series shall not be listed on equity option classes, options on ETFs, or options on TIRs in a new expiration year if the national average daily contract volume, excluding LEAP and FLEX series, for that options class during the preceding three calendar months is less than 1,000 contracts. The preceding volume threshold does not apply during the first six months an equity option class, option on an ETF, or option on a TIR is listed on any exchange.
|
|
|
Post by mnkdfann on Jan 20, 2020 15:32:49 GMT -5
Why? I believe the closing price last week was $1.51. Perhaps the powers that be (call option writers) pushed the SP just over the strike of $1.50 at the last second so they could unload their remaining shares on the call option holders? Would that suggest they are anticipating the SP to fall at this point? If they didn't want their shares and don't see the price appreciating further, it would certainly be one way to get rid of them at a predetermined price. Probably, but that doesn't mean they are correct. Perhaps it is a way to sell a bunch, without the selling pressure dropping the price.
|
|
|
Post by mnkdfann on Jan 20, 2020 15:13:47 GMT -5
I thought "IN THE MONEY" was the strike price plus the premium? Does that mean you bought your $1.50 options for $ .01 each?? Doubt that.... OK, but why no MM fight at the bell to lock ($1.49)? We have all become accustomed to watching this battle play out on options expiry day. I KNOW NOTHING ABOUT OPTIONS, this is just an observation that may have an easy explanation. Why? I believe the closing price last week was $1.51. Perhaps the powers that be (call option writers) pushed the SP just over the strike of $1.50 at the last second so they could unload their remaining shares on the call option holders?
|
|